Intestinal epithelial mucosal surface glycoconjugates

Intestinal epithelial mucosal surface glycoconjugates are a complex assembly of glycoproteins, glycolipids, and proteoglycans that form the glycocalyx and the overlying mucus layer of the gastrointestinal tract (Source: NIH). These molecules, including major secreted mucins like MUC2 and membrane-bound mucins like MUC1 and MUC17, serve as the primary physical and chemical barrier between the host epithelium and the luminal environment (Source: PubMed). They play critical roles in lubricating the intestinal surface, regulating nutrient absorption, and mediating interactions with the gut microbiota by providing adhesion sites and carbon sources (Source: ScienceDaily). In disease states such as inflammatory bowel disease (IBD) and colorectal cancer, the glycosylation patterns of these conjugates are often altered, leading to barrier dysfunction and aberrant immune signaling (Source: JCI Insight). Therapeutically, these glycoconjugates are targeted to enhance mucosal protection, inhibit pathogen adhesion, and facilitate site-specific drug delivery (Source: Science). For example, mucoprotective agents like rebamipide stimulate their production to reinforce the physical barrier against injury (Source: StatPearls). Additionally, innovative drug delivery systems such as GlycoCaging leverage the unique enzymatic environment of the mucosal surface to achieve site-specific release of anti-inflammatory drugs (Source: Science). Monoclonal antibodies like GM35 have also been developed to target specific glycans on the mucosal surface to promote epithelial repair and wound healing (Source: JCI Insight).

Other names

Intestinal glycocalyxIntestinal mucus layerBrush border glycoconjugatesIntestinal mucosal glycansCell surface glycoconjugatesMucin-type glycoproteins

The therapeutic targeting of these glycoconjugates involves several mechanisms: 1) stimulation of mucin and glycoconjugate synthesis to enhance barrier integrity (e.g., rebamipide); 2) competitive inhibition of pathogen adhesion to glycan receptors; 3) ligation of specific glycan epitopes to trigger intracellular pro-repair signaling (e.g., GM35); and 4) enzymatic release of drugs from glycoconjugate-based delivery systems (Source: Science, JCI Insight, StatPearls).